1Lun·

Still looking for a share in the pharmaceutical sector?

Just tell us the title and preferably why you find it so interesting.

For your information $CAMX (-1,89 %) I already own

Many thanks in advance for all answers

32 Comentarios

Dividendenopi👴@Dividendenopi

1Lun

$NOVO B is currently on special offer 😉😇

•

Tenbagger2024@Tenbagger2024

1Lun

@Dividendenopi Software shares also

•

lukaslr91@lukaslr91

1Lun

@Dividendenopi NOVO has been on sale for more than a year and it is steadily...

••

Dividendenopi👴@Dividendenopi

1Lun

@Tenbagger2024 I'm really thinking about whether I should do without dividends for a bit 🤷‍♂️🤔🤔 and look for a few entry points

••

Tenbagger2024@Tenbagger2024

1Lun

@Dividendenopi
Good question, which software will survive? AI is already changing things

•

Dividendenopi👴@Dividendenopi

1Lun

@Tenbagger2024 That is a valid objection. We certainly need to reassess some companies. However, AI also brings advantages that are not yet so obvious. Let's run through the current reporting quarter and then sweep up the broken pieces and see what happens next

•

Tenbagger2024@Tenbagger2024

1Lun

@Dividendenopi
Because uncertainty about software will remain on the market.

•

Dividendenopi👴@Dividendenopi

1Lun

@Tenbagger2024 that's the way it is, it could have been different 🤷‍♂️

•

Tenbagger2024@Tenbagger2024

1Lun

@Dividendenopi
Not good for the project right now either 😭

•

Dividendenopi👴@Dividendenopi

1Lun

@Tenbagger2024 jo mei sogt da Bayer. 🙃 You sound a bit pissed off, but you should be above such days.

•

Get_Rich_or_Die_Tryin@Get_Rich_or_Die_Tryin

1Lun

@Dividendenopi lost too much weight too quickly.🤣 Fortunately, the yo-yo effect will probably not happen here.🤷🏼‍♂️

••

Ver todas las 11 respuestas adicionales

Smudo@Smudeo

1Lun

$PFE

•

Valesthor@Valesthor

1Lun

$AZN is very broadly positioned in oncology incl. other things listed on the NYSE since yesterday looks very robust good growth.

$HIMS currently has problems with America as generics are being put on hold there to help large companies like Elli Lilly. But is very broadly positioned in telemedicine and online pharmacies. Probably has the greatest growth opportunities but also more risk AstraZeneca is more stable.

•

investment_wizard_2286@investment_wizard_2286

1Lun

$RVMD is strong in oncology. 2 billion in cash available plus additional funds from a partnership.
Unfortunately I got out before the rocket ignited

•

Rookie@Rookie

1Lun

$UCB Specialized in neurological diseases.

•

Florian Simon@FloFinance

1Lun

$ABBV has an exciting range of drugs in the fields of immunology and oncology, among others. I estimate that the Group will continue to grow diligently.

•